Table 2.
Demographic and clinical characteristics of PWH hospitalized with COVID-19 by severity of COVID-19 disease.
| No./total (%) of patients | ||||
|---|---|---|---|---|
| Hospitalized (n = 106) |
Admitted to ICU (n = 31) |
Intubated (n = 16) |
Died (n = 12) |
|
| Demographic characteristics | ||||
| Female | 39/106 (37) | 12/31 (39) | 5 (31) | 4 (33) |
| Age in 2020, y | ||||
| <30 | 5/106 (5) | 0/31 (0) | 0/16 (0) | 0/12 (0) |
| 30–39 | 10/106 (9) | 4/31 (13) | 2/16 (13) | 1/12 (8) |
| 40–49 | 18/106 (17) | 2/31 (7) | 0/16 (0) | 2/12 (17) |
| 50–59 | 34/106 (32) | 9/31 (29) | 4/16 (25) | 2/12 (17) |
| ≥60 | 39/106 (37) | 16/31 (52) | 10/16 (63) | 7/12 (58) |
| Race/ethnicity | ||||
| Non-Hispanic Black | 70/106 (66) | 7/31 (23) | 4/16 (25) | 2/12 (17) |
| Non-Hispanic White | 17/106 (16) | 19/31 (61) | 10/16 (63) | 7/12 (58) |
| Hispanic | 12/106 (11) | 3/31 (10) | 1/16 (6) | 3/12 (25) |
| Other | 7/106 (7) | 2/31 (7) | 1/16 (6) | 0/12 (0) |
| Clinical characteristics a | ||||
| Lowest CD4 count, cells/mm3 | ||||
| <200 | 63/105 (60) | 18/31 (58) | 9/16 (56) | 8/12 (67) |
| 200–349 | 20/105 (19) | 4/31 (13) | 2/16 (13) | 1/12 (8) |
| 350–499 | 13/105 (12) | 6/31 (19) | 2/16 (13) | 1/12 (8) |
| ≥500 | 9/105 (9) | 3/31 (10) | 3/16 (19) | 2/12 (17) |
| Current CD4 count, cells/mm3 | ||||
| <200 | 18/98 (18) | 6/26 (23) | 4/15 (27) | 3/11 (27) |
| 200–349 | 20/98 (20) | 5/26 (19) | 2/15 (13) | 3/11 (27) |
| 350–499 | 11/98 (11) | 3/26 (12) | 2/15 (13) | 1/11 (9) |
| ≥500 | 49/98 (50) | 12/26 (46) | 7/15 (47) | 4/11 (36) |
| Currently on ART | 103/106 (97) | 29/31 (94) | 14/16 (88) | 10/12 (83) |
| Undetectable viral load (<50 copies/mL) | 84/100 (84) | 25/29 (86) | 13/15 (87) | 10/12 (83) |
| Diabetes | 43/100 (43) | 15/29 (52) | 9/16 (56) | 6/11 (55) |
| Hypertension | 60/100 (60) | 19/29 (66) | 11/16 (69) | 8/11 (73) |
| CKD (eGFR), mL/min/1.73 m2 | ||||
| ≥60 | 70/104 (67) | 15/30 (50) | 6/16 (38) | 5/12 (42) |
| <60 | 34/104 (33) | 15/30 (50) | 10/16 (63) | 7/12 (58) |
| BMI, kg/m2 | ||||
| <30 | 37/96 (39) | 9/26 (35) | 3/13 (23) | 2/11 (18) |
| ≥30 | 59/96 (62) | 17/26 (65) | 10/13 (77) | 9/11 (82) |
| ASCVD risk score, mean (SD) | 11.9% (10.3%) | 11.7% (10.7%) | 17.2% (13.4%) | 19.6% (12.9%) |
| Cigarette smoker (ever) | 50/106 (47) | 13/31 (50) | 5/16 (31) | 6/12 (50) |
| COPD | 16/100 (16) | 4/29 (14) | 1/16 (6) | 1/11 (9) |
| HCV | 20/100 (20) | 8/29 (28) | 4/16 (25) | 3/11 (27) |
| FIB-4 score | ||||
| ≤3.25 | 92/99 (93) | 25/28 (89) | 14/16 (88) | 11/11 (100) |
| >3.25 | 7/99 (7) | 3/28 (11) | 2/16 (13) | 0/11 (0) |
| FIB-4 score | ||||
| ≤1.45 | 61/99 (62) | 20/28 (71) | 11/16 (69) | 8/11 (73) |
| >1.45 | 38/99 (38) | 8/28 (29) | 5/16 (31) | 3/11 (27) |
Percent may not sum to 100 due to rounding.
Abbreviations: ART, antiretroviral therapy; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CKD, chronic kidney disease; CNICS, Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; FIB-4, Fibrosis-4 scoring system for liver fibrosis; HCV, Hepatitis C virus; PWH, people with HIV.
a
Most recent value prior to one-week preceding COVID-19 diagnosis.